Aquatic Capital Management LLC Takes $374,000 Position in GeneDx Holdings Corp. (NASDAQ:WGS)

Aquatic Capital Management LLC acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,867 shares of the company's stock, valued at approximately $374,000.

A number of other large investors have also added to or reduced their stakes in WGS. Nebula Research & Development LLC purchased a new position in GeneDx in the fourth quarter worth about $378,000. Lord Abbett & CO. LLC bought a new stake in GeneDx during the 4th quarter worth approximately $48,458,000. Oberweis Asset Management Inc. raised its stake in GeneDx by 1.2% during the 4th quarter. Oberweis Asset Management Inc. now owns 123,500 shares of the company's stock valued at $9,492,000 after purchasing an additional 1,500 shares during the period. Science & Technology Partners L.P. bought a new stake in GeneDx during the fourth quarter worth approximately $30,821,000. Finally, Voya Investment Management LLC bought a new stake in GeneDx in the fourth quarter worth $292,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

GeneDx Stock Performance

NASDAQ:WGS traded down $1.56 during trading hours on Thursday, hitting $55.78. 603,654 shares of the company traded hands, compared to its average volume of 732,257. The firm has a 50-day moving average of $91.98 and a 200 day moving average of $82.64. GeneDx Holdings Corp. has a twelve month low of $18.80 and a twelve month high of $117.75. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -28.46 and a beta of 1.96. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.17. The company had revenue of $87.12 million for the quarter, compared to analyst estimates of $79.90 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. On average, analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Insider Activity at GeneDx

In other news, CEO Katherine Stueland sold 10,559 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the completion of the transaction, the chief executive officer now directly owns 14,865 shares of the company's stock, valued at $1,437,594.15. This represents a 41.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 388 shares of GeneDx stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total value of $43,878.92. Following the completion of the sale, the chief financial officer now directly owns 3,337 shares of the company's stock, valued at approximately $377,381.33. This trade represents a 10.42 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 139,390 shares of company stock valued at $13,043,288. Corporate insiders own 27.30% of the company's stock.

Wall Street Analyst Weigh In

WGS has been the topic of several recent analyst reports. TD Securities reduced their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Wells Fargo & Company lowered their price objective on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group boosted their price target on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, GeneDx currently has an average rating of "Moderate Buy" and a consensus target price of $78.14.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.